How to Invest in Gene editing stocks
Last updated July 2026
Short answer
You can invest in Gene editing stocks by buying the individual stocks that fit the thesis (BEAM, CRSP, NTLA), holding an ETF proxy like ARKG, or building a focused Gene editing stocks basket. Gene editing companies aim to treat disease by changing DNA rather than managing symptoms. The science has produced approved therapies, which moved the field from speculative to real, but most companies in it remain pre-revenue and dependent on clinical trial outcomes. This is the highest-risk corner of healthcare: individual stocks can move by half on a single readout, in either direction.
What gets a stock into the Gene editing stocks theme?
Revenue or pipeline focused on gene editing and gene therapy platforms, including CRISPR-based approaches and the delivery technologies behind them.
What stocks are in the Gene editing stocks theme?
Every public name that fits the Gene editing stocks thesis, with the rationale for inclusion. Click any ticker for the full stock guide. The basket above starts equal-weighted; you set your own target weights inside Walnut.
Beam Therapeutics (NASDAQ: BEAM) develops precision genetic medicines using base editing, a technique it helped invent that rewrites a single letter of DNA without cutting both str
CRISPR Therapeutics AG is a Swiss-American biopharmaceutical company headquartered in Zug, Switzerland, with principal research operations in Boston, Massachusetts.
Intellia Therapeutics, Inc.
Ultragenyx Pharmaceutical (NASDAQ: RARE) develops and sells treatments for rare and ultra-rare genetic diseases, conditions with small patient populations and often no approved the
Vertex Pharmaceuticals is a Boston-based biotechnology company that designs medicines targeting the root molecular cause of serious diseases rather than only their symptoms.
For the full roundup of the individual names in this theme, grouped by the role each one plays, read best gene editing stocks.
Which ETFs cover Gene editing stocks?
If you want the theme as a single ticker rather than as a basket, these are the ETFs people most commonly use. Each has trade-offs (concentration, expense ratio, sector overlap) covered in the individual ETF guides.
The bottom line on Gene editing stocks
Gene editing stocks is best expressed as a focused basket of the names that actually fit the thesis rather than a diluted sector ETF. Core names include BEAM, CRSP, NTLA. In a portfolio it works as a satellite tilt you size deliberately, not a core holding.
FAQ
How do I invest in gene editing stocks?
+
Most of these companies are pre-revenue and binary on trial results, so diversification across several matters more here than almost anywhere else, and position sizing matters more still. A fund such as ARKG spreads the risk. Walnut is informational and not an investment adviser.
What is CRISPR and why does it matter?
+
CRISPR is a technique for making targeted changes to DNA far more cheaply and precisely than earlier methods. It moved gene editing from a slow laboratory process to something that can be developed into therapies at scale. The commercial question is not whether the science works, which is settled, but which companies can turn it into approved, reimbursed treatments.
Why are gene editing stocks so volatile?
+
Because their value rests almost entirely on future outcomes with binary results. A successful late-stage trial can validate a platform and multiple candidates behind it; a failure or a safety signal can eliminate a programme and years of expected value at once. With no current revenue to anchor valuation, the share price moves on information rather than earnings.
Have any gene editing therapies been approved?
+
Yes, which is the change that made this an investable theme rather than a research story. Approvals demonstrated that the regulatory path exists and that the science can reach patients. The remaining commercial questions are manufacturing at scale, pricing for one-time treatments that can cost a great deal, and whether health systems will reimburse them.
What are the risks of gene editing stocks?
+
Clinical failure and safety signals, which are the dominant risks. Cash burn and repeated equity issuance that dilutes existing shareholders. Manufacturing complexity for living therapies. Reimbursement uncertainty for very expensive one-time treatments. And patent disputes, which have been unusually contentious in this field.
Does Walnut recommend which gene editing stocks to buy?
+
No. Walnut is not a registered investment adviser, and this is among the highest-risk areas of the listed market. It lets you build a basket from constituents you choose, size it deliberately against your portfolio, and approve every trade yourself at your own broker.
Build the Gene editing stocks basket in Walnut
Walnut's AI assistant takes the thesis above, proposes 5 to 6 constituents with target weights, and lets you fund the basket through your existing broker. You approve every order; we never trade on your behalf.
Other themes
- AI infrastructure. Picks and shovels of the AI buildout: GPUs, networking, foundries, and the software platforms training the largest models.
- Data center power and cooling. The grid, switchgear, liquid cooling, and electrical contracting that AI data centers can't run without.
- Semiconductors. The full chip stack: designers, foundries, equipment makers, materials suppliers, and packaging specialists.
- Defense and modernization. Software, sensors, and specialty materials at the center of US and allied defense buildouts.
- Critical materials. Rare earths, specialty metals, and strategic materials at the center of supply chain reshoring.
Walnut is informational, not investment advice. Theme membership is descriptive, not prescriptive; nothing on this page should be read as a recommendation. Always verify current financials and your own circumstances before investing.